You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • FRI0401 Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with The Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of The Korean Society of Spondyloarthritis Research

Article Text

Article menu
Download PDFPDF
Poster Presentations
Spondyloarthritis - clinical aspects (other than treatment)
FRI0401 Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with The Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of The Korean Society of Spondyloarthritis Research
  1. H.W. Kim1,
  2. S.-H. Lee2,
  3. H.J. Baek3,
  4. T.-H. Kim4,
  5. Y.-G. Kim5,
  6. on behalf of Korean Society of Spondyloarthritis Research
  1. 1Internal Medicine, Division of Rheumatology, Eulji General Hospital
  2. 2Internal Medicine, Division of Rheumatology, Center of Arthritis and Rheumatism, Kyung Hee University Hospital at Gangdong
  3. 3Internal Medicine, Division of Rheumatology, Gachon University Gil Hospital
  4. 4Internal Medicine, Division of Rheumatology, Hanyang University Hospital for Rheumatic Diseases
  5. 5Internal Medicine, Division of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic Of

Abstract

Background Patients who develop an active tuberculosis infection (TI) during tumor necrosis factor (TNF) inhibitor treatment typically discontinue TNF inhibitor and receive standard anti-tuberculosis treatment. However, there is currently insufficient information on patient outcomes following resumption of TNF inhibitor treatment during ongoing anti- tuberculosis treatment.

Objectives Our study designed to investigate the safety of resuming TNF inhibitors in ankylosing spondylitis (AS) patients who developed TI as a complication of the use of TNF inhibitors.

Methods Through the nationwide registry of the Korean Society of Spondyloarthritis Research, 3929 AS patients were recruited who were prescribed TNF inhibitors between June 2003 and June 2014 at fourteen referral hospitals. Clinical information about the patients who experienced TI after exposure to TNF inhibitors was analyzed. The clinical features of resumers and non-resumers of TNF inhibitor were compared and the outcome of TI was surveyed individually.

Results Fifty-six AS patients were treated for TI associated with TNF inhibitors. Among them, 23 patients resumed TNF inhibitors and these patients were found to be exposed to TNF inhibitors for a longer period of time and experienced more frequent disease flare up after discontinuation of TNF inhibitors compared with those who did not resume. Fifteen patients resumed TNF inhibitors during anti-tuberculosis treatment (early resumers) and 8 after completion of TI treatment (late resumers). Median time to resuming TNF inhibitor from TI was 3.3 and 9.0 months in the early and late resumers, respectively. TI was treated successfully in all resumers and did not relapse in any of them during follow-up (median 33.8 (IQR; 20.8–66.7) months).

Figure

Conclusions TI were treated successful in our AS patients, even when given concomitantly with TNF inhibitors. We suggest that early resuming TNF inhibitors in AS patients could be safe under effective coverage of the TI.

Disclosure of Interest None declared

https://doi.org/10.1136/annrheumdis-2016-eular.2852

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.